GlassScriptPhysician profile
Aneshia Nunley
NPI 1184388142
$5,852.45
in general payments reported to CMS, 2019-2025
33 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $2,016 · 2023: $1,755 · 2024: $67.94 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.83 |
| Education | $119.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $834.78 | 2021-2023 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $644.41 | 2022-2025 | Jynarque, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $502.45 | 2021-2023 | |
| Baxter Healthcare | $473.00 | 2022-2023 | Renal - Dianeal Solution, Renal - Chronic |
| Vifor Pharma, INC. | $365.36 | 2021-2023 | Veltassa, Korsuva |
| Teva Pharmaceuticals USA, INC. | $356.02 | 2025 | Uzedy, Austedo Xr |
| Calliditas Therapeutics US INC. | $324.38 | 2022-2023 | Tarpeyo |
| Neurocrine Biosciences, INC. | $313.09 | 2024-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $257.31 | 2021-2023 | Ultomiris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.70 | 2025 | Caplyta |
| Abbvie INC. | $220.96 | 2025 | |
| Mallinckrodt Hospital Products INC. | $184.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.00 | 2025 | Cobenfy |
| Opko Pharmaceuticals, LLC | $148.52 | 2021-2023 | Rayaldee |
| Alkermes, INC. | $129.10 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $113.37 | 2022 | |
| Amgen INC. | $71.56 | 2022-2023 | Tavneos |
| Aurinia Pharma U.S., INC. | $71.49 | 2022-2023 | Lupkynis |
| Fresenius USA Marketing, INC. | $60.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $58.16 | 2025 | Invega Sustenna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.32 | 2023 | |
| Travere Therapeutics, INC. | $37.39 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.49 | 2025 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $36.02 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $28.53 | 2023 | Purified Cortrophin Gel |
| Idorsia Pharmaceuticals US INC | $21.36 | 2025 | Quviviq |
| Glaxosmithkline, LLC. | $18.07 | 2023 | Benlysta |
| Supernus Pharmaceuticals, INC. | $17.12 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $17.10 | 2025 | Secuado |
| Horizon Therapeutics Plc | $15.97 | 2023 | Krystexxa |
| Novo Nordisk INC | $15.51 | 2025 | Wegovy |
| Vanda Pharmaceuticals INC. | $14.62 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $13.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneshia Nunley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.